ClinVar Miner

Submissions for variant NM_000169.3(GLA):c.350T>G (p.Ile117Ser)

dbSNP: rs12392549
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001260301 SCV001437223 pathogenic Fabry disease 2020-09-01 criteria provided, single submitter clinical testing Variant summary: GLA c.350T>G (p.Ile117Ser) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183291 control chromosomes. c.350T>G has been reported in the literature in multiple individuals affected with adult/late-onset Fabry Disease (example, Stepien_2017, Germain_2020) and in Fabry patients with predominant renal manifestations (example McCloskey_2018). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal alpha Gal-A enzyme activity (Benjamin_2016). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.